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Abstract
Background: Activation of nuclear factor erythroid 2-related factor (Nrf2), which belongs to the basic leucine
zipper transcription factor family, is a strategy for cancer chemopreventive phytochemicals. It is an important
regulator of genes induced by oxidative stress, such as glutathione S-transferases, heme oxygenase-1 and
peroxiredoxin 1, by activating the antioxidant response element (ARE). We hypothesized that (1) the citrus coumarin
auraptene may suppress premalignant mammary lesions via activation of Nrf2/ARE, and (2) that Nrf2 knockout (KO)
mice would be more susceptible to mammary carcinogenesis.
Methods: Premalignant lesions and mammary carcinomas were induced by medroxyprogesterone acetate and
7,12-dimethylbenz[a]anthracene treatment. The 10-week pre-malignant study was performed in which 8 groups of
10 each female wild-type (WT) and KO mice were fed either control diet or diets containing auraptene (500 ppm).
A carcinogenesis study was also conducted in KO vs. WT mice (n = 30-34). Comparisons between groups were
evaluated using ANOVA and Kaplan-Meier Survival statistics, and the Mann-Whitney U-test.
Results: All mice treated with carcinogen exhibited premalignant lesions but there were no differences by
genotype or diet. In the KO mice, there was a dramatic increase in mammary carcinoma growth rate, size, and
weight. Although there was no difference in overall survival, the KO mice had significantly lower mammary tumor-
free survival. Also, in the KO mammary carcinomas, the active forms of NF-B and b-catenin were increased
~2-fold whereas no differences in oxidized proteins were observed. Many other tumors were observed, including
lymphomas. Interestingly, the incidences of lung adenomas in the KO mice were significantly higher than in the
WT mice.
Conclusions: We report, for the first time, that there was no apparent difference in the formation of premalignant
lesions, but rather, the KO mice exhibited rapid, aggressive mammary carcinoma progression.
Background
Breast cancer is the most common cancer among Amer-
ican women, except for skin cancers. The chance of
developing invasive breast cancer at some time in a
woman’s life is about 1 in 8 (12%). In 2009, an estimated
192,370 new cases of invasive breast cancer will be diag-
nosed among women in the United States [1]. Many
risk factors have been attributed to breast cancer occur-
rence. Genetic susceptibility accounts for only ~10% of
human breast cancer [1,2]. Known environmental risk
factors include radiation, obesity, and alcohol use [1,2].
Nuclear factor erythroid 2-related factor (Nrf2) is an
important regulator of genes induced by oxidative stress,
such as glutathione S-transferases (GSTs), heme oxyge-
nase-1 (HO-1) and peroxiredoxin 1, by activating the
antioxidant response element (ARE) [3]. Reactive oxygen
species (ROS) are known to activate oncogenic tran-
scription factors such as AP-1 and NF-Bt h a th a v e
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nogenesis [3]. It has also been noted that Nrf2 defi-
ciency in mice shows an increased risk of chemical
carcinogenesis and Nrf2 loss may contribute to tumori-
genesis [3]. However, the effects of Nrf2 deficiency in
breast cancer have not yet been explored.
Many cancer chemopreventive agents, in particular
those that are naturally occurring, boost cellular antioxi-
dant defenses [4]. Evidence is mounting that many of
these phytochemicals activate the ARE through Nrf-2.
Orally administered AUR induces GST activities via
activation of Nrf2, since these effects were significantly
attenuated in Nrf2(-/-) knockout (KO) mice [5]. Based
on these studies, we hypothesized that AUR could sup-
press mammary carcinogenesis via activation of Nrf2/
ARE. In summary although many chemopreventive phy-
tochemicals are known to activate cellular antioxidant
defenses through the ARE, direct evidence that their
chemopreventive effects against mammary carcinogen-
esis are due to this effect is limited.
Oxidative stress is a condition of increased oxidant
production in animal cells characterized by the release
of free radicals, resulting in cellular degradation. Oxida-
tive stress resulting from excess ROS and/or deficiencies
in antioxidant capabilities may play a role in breast can-
cer etiology [6]. For example, a growing body of evi-
dence suggests that natural and synthetic estrogens,
which are oxidized to form quinones, are involved in
breast cancer [7]. In a population-based, case-control
study (654 cases, 605 controls), African American
women harboring the mitochondrial DNA G10398 poly-
morphism exhibited an increased risk of invasive breast
cancer (OR 1.60; 95% CI, 1.10-2.31, P = 0.013) [8].
MtDNA G10398A may be involved in altered structure
of Complex I, which could lead to increased ROS [8].
Recently, a nested case-control study of postmenopausal
women reported that women with genetic polymorph-
isms of Nrf2, NAD(P)H quinone oxidoreductase
(NQO1), and HO-1 that favored iron-generated oxida-
tive stress were at higher risk of breast cancer [6] An
epidemiological study by Santella and colleagues found
that women with higher plasma levels of oxidative pro-
tein damage (i.e. protein carbonyls) were at higher risk
for breast cancer [9]. These studies suggest a role of oxi-
dative stress in breast cancer that may be attenuated by
chemopreventive agents.
In order determine whether phytochemicals can pre-
vent mammary carcinogenesis via activation of Nrf2/
A R E ,f i r s ti tm u s tb ed e m o n s t r a t e dt h a tN r f 2 / A R Ei s
involved in mammary carcinogenesis. To our knowl-
edge, no mammary carcinogenesis studies have ever
been done in Nrf2 knockout mice. Thus, to address this
critical gap in knowledge, we conducted a mammary
carcinogenesis study in Nrf2 knockout mice. We report,
for the first time, that there was no apparent differ-
ence in the formation of premalignant lesions, but
rather, the KO mice exhibited rapid, aggressive
mammary carcinoma progression. Many questions
remain as to the mechanism, which we will explore
in future studies.
Methods
Auraptene
Auraptene (AUR), a natural product isolated from
citrus, was initially purchased from LKT laboratories,
Inc. (West St. Paul, MN) for the previous studies and
for the comparison study (see below). In this regard,
d u et ot h el a r g eq u a n t i t yo fA U Rn e e d e dt om i xi nt h e
diet for the premalignant study, it became necessary to
synthesize AUR.
Synthesis of Auraptene
The synthesis of AUR was based on a literature proce-
dure [10], modified as follows. Geranyl chloride (42 g,
0.24 mol), synthesized as reported elsewhere [11], was
added to a 2-L round bottom flask along with acetone
(800 mL), potassium carbonate (45 g, 0.32 mol), and
7-hydroxycoumarin (35.8 g, 0.22 mol), obtained from
Sigma-Aldrich. The reaction mixture was allowed to stir
a n dh e a t e da tag e n t l er e f l u xu n d e ra na r g o na t m o -
sphere for about 3 days, when thin layer chromatogra-
phy (TLC) showed that no more 7-hydroxycoumarin
was present. The reaction mixture was then cooled, fil-
tered, and evaporated to dryness. The residue was dis-
solved in ethyl acetate and filtered. Removal of the
solvent gave crude product (65 g), which was heated in
hexanes along with 2 g of activated charcoal. After the
product had dissolved, the mixture was filtered hot. The
crystals that formed as the mixture cooled were filtered,
dissolved in a toluene, hexanes solvent mixture and sub-
jected to flash chromatography (7:1 toluene, hexanes).
After collecting and combining the appropriate frac-
tions, the solvent was removed, and the residue was
crystallized from hexanes to give ~30 g of product. The
1Ha n d
13C NMR spectra matched those of the authen-
tic sample. The compound also co-eluted on TLC with
the authentic sample. The synthesis of auraptene was
carried out by Dr. William H. Johnson, Jr. in the labora-
tory of Dr. Christian P. Whitman (The University of
Texas at Austin). Hence we named the synthetic AUR
as “UT-AUR”.
Comparison study: LKT-AUR vs. UT-AUR
We conducted a comparison study to determine if the
synthetic AUR (UT-AUR) possessed the same activities
as the AUR purchased from LKT (LKT-AUR). This study
was conducted exactly the same way as the original study
in which we showed that AUR could significantly
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KO mice [5]. The results of the study were consistent
with our previous study, and the synthetic AUR pos-
sessed the same activity as that from LKT (Additional
File 1: Figure S1). UT-AUR was then shipped to Dyets,
Inc. (Bethlehem, PA) where it was mixed with AIN76A
and formed into pellets (formulation sheet available upon
request). These pellets were used for the AUR arms of
the premalignant study.
Animals
Wild-type (WT) and Nrf2(-/-) knockout (KO) mice on
an ICR background were bred and genotyped in our
f a c i l i t yf o rt h ep r o j e c t .T h e yw e r eh o u s e di nat e m p e r a -
ture and humidity controlled AAALAC accredited facil-
ity under a normal 12-hour light/dark cycle. LSUHSC
Institutional Animal Care and Use Committee approved
the procedures in accordance with NIH guidelines. Mice
were allowed access to food (AIN-76A) and water ad
libitum. Female mice at 5-6 weeks of age were used for
the studies below. The carcinogenesis models described
below were adapted according to Aldaz & co-workers
[12]. Body weights for the premalignant study and the
tumor study are shown in Additional File 1: Figures S3,
S4, and S5. Overall, there were no dramatic effects on
body weights by any of the treatments.
Premalignant Study
A 10-week pre-malignant breast cancer study was per-
formed in which 8 groups of 10 each female WT and
Nrf2 KO mice were fed either control diet (AIN76A,
Dyets Inc. Bethlehem, PA) or diets containing AUR (500
ppm). Mice were shaved on the dorsal flank with clip-
pers and those mice that were to be dosed with carcino-
gen were first injected with medroxyprogesterone
acetate (15 mg, sc, purchased from Pfizer Inc., NY, NY).
This was considered day 1 of the study. One week later,
mice were then administered vehicle (0.1 mL/25 g bw
corn oil, negative controls) or dosed with and 7,12-
dimethylbenz[a]anthracene (DMBA, 40 mg/kg bw, oral
gavage, once/wk for 4 consecutive weeks, purchased
from Sigma-Aldrich) (groups labeled as “DMBA”)t o
induce premalignant lesions. All treatments with DMBA
were conducted in a light-protected biosafety cabinet,
since DMBA is hazardous and light-sensitive. At the
end of the 10 weeks, mice were euthanized by CO2
asphyxiation in a pre-charged chamber, and mammary
glands were collected. Mammary fat pads were also
fixed in 10% neutral buffered formalin overnight, then
treated with graded alcohols followed by paraffin-
embedding, sectioning at 4 μm, and H&E staining.
Livers were collected for GST activity assays. Additional
mammary fat pads were snap-frozen in liquid nitrogen
and stored at -80°C for later analysis. Snap-frozen
mammary epithelial tissue was isolated from mammary
glands using hyaluronidase and collagenase as previously
described [13].
Tumor Study
Groups of 10 mice each (WT & KO) were administered
vehicle for the negative controls. Groups of 34 mice
(WT) and 30 mice (KO) were dosed with medroxypro-
gesterone acetate and DMBA exactly as was done in the
premalignant study. Mice were palpated twice a week
for tumors, and body weights were recorded weekly.
Tumors were measured using digital calipers and tumor
volume (mm
3) was calculated using the following for-
mula, based on the assumption of a near-spherical
tumor shape: V = ((l + w)/4)
3 *1 . 3 3*P I ,w h e r el =
length, w = width. Necropsies were planned as soon as a
mouse appeared moribund or the tumor volume was ≥
1800 mm
3.M i c ew e r ee u t h a n i z e dv i aC O 2 asphyxiation
in a pre-charged chamber, and necropsied immediately.
Criteria for euthanasia were based, not only on body
weight loss or coat condition, but on overall sickness
behavior and body condition, described recently by
Paster and colleagues [14]. Individual mice were meticu-
lously tracked throughout the entire study by use of ear
tags. Data for every individual mouse was recorded on a
chart, including the location of the tumor and any other
observations, such that the histopathology analyses
could be matched to the individual tumor history
(growth rate over time, etc.). Necropsies were performed
on all mice. Anything that looked like a tumor anywhere
in the body was taken for histology, as well as spleens,
livers, mammary fat pads, lungs, and occasionally
bone and brain to check for metastases. Tumors were
verified by two independent pathologists as mammary
carcinomas.
Western blot analysis
Mammary carcinomas previously snap-frozen in liquid
nitrogen and stored at -80°C were pulverized in a mor-
tar and pestle in liquid nitrogen over dry ice. Tissue was
never allowed to thaw. Approx. 100 mg of pulverized
tissues were lysed in RIPA buffer, further processed, and
normalized by protein concentration. Protein concentra-
tion was estimated using the bicinchoninic acid method
comparing to a BSA standard curve (Thermo Scientific,
Rockford, IL). Oxyblot: samples were derivatized using
2,4-dinitrophenylhydrazine as described by Levine &
colleagues [15], resolved on a polyacrylamide gel then
electroblotted onto a membrane filter (PVDF), and
probed for DNP-ylated proteins (indicating protein car-
bonyls). This procedure was conducted with the aid of
the OxyBlot™ Protein Oxidation detection kit from
Millipore (Temecula, CA) following manufacturer’s
instructions. NF-B: Samples were probed with anti-
phospho-Ser
529-p65 NF-B antibody (SA Biosciences,
Inc.), and detected with enhanced chemiluminescence.
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stain as a loading control (G Biosciences, St. Louis,
MO). b-catenin: Protein extracts were subjected to poly-
acrylamide gel electrophoresis using the 4-12% NuPAGE
gel system (Invitrogen), transferred to PVDF (Millipore)
membranes and immunoblotted. Antibodies included
active b-catenin (05-665) & total b-catenin (06-734)
from Upstate and b-actin (sc-47778) from Santa Cruz
Biotech. Membranes were probed with HRP-conjugated
secondary antibodies for one hour. Membranes were
washed with TBST and deioninzed water prior to visua-
lization by enhanced chemiluminescence (Pierce). Films
for each respective blot were scanned and band intensity
was evaluated using Image-J software.
Histopathology
Mice were injected with 2-Bromodeoxyuridine (BrdU,
50 mg/kg ip) 2 h prior to sacrifice for the premalignant
study. Whole mounts of mammary fat pads were stained
with alum carmine for morphometric analysis as pre-
viously described by Russo & colleagues [16]. Formalin-
fixed, paraffin embedded sections were also cut to 5 μ
and stained with H&E for histopathological analysis as
described [16]. Cell proliferation was detected by posi-
tive nuclear immunohistochemical staining for BrdU in
the premalignant study.
Liver cytosolic GST assays
All samples were homogenized in 0.05 M Tris, pH 7.4
buffer containing 0.25 M sucrose, spun at 10,000 × g,
and then the supernatant was transferred into a new
tube and centrifuged at 100,000 × g for 60 minutes at 4°
C. Bradford Protein Assay performed to estimate protein
concentration using BSA as a standard. GST activities
were determined using 1-chloro-2,4-dinitrobenzene
(CDNB) and 1,2-dichloro-4-nitrobenzene (DCNB) as
substrates [5,17]. Both CDNB and DCNB were pur-
chased from Acros (NJ). Briefly, liver cytosolic samples
were analyzed using a spectrophotometer reading 340
and 345 nm, respectively, and a cell temp set at 25°C, a
lag time of 10 seconds and a rate time of 60 seconds.
Caution was given to minimize delay between preparing
samples and loading. Activities were calculated
using the extinction coefficient of 9.6 mM
-1cm
-1 and 8.5
mM
-1cm
-1, respectively.
Quantitative real-time pcr array
Mammary carcinomas snap-frozen in liquid nitrogen
were ground in a mortar and pestle over liquid nitrogen.
~30 mg of powdered tissue was then homogenized and
sonicated in lysis buffer containing 2-mercaptoethanol,
then subject to RNA isolation and DNase digestion
using a mini-spin kit (GE Healthcare). Quantity, purity,
and integrity of RNA isolates were verified using Agilent
Analysis. Complementary DNA was synthesized from
RNA in a thermocycler using qScript™ cDNA SuperMix
(Quanta Biosciences, Inc.) according to manufacturer’s
directions. Finally, cDNA was mixed with the SYBR
green master mix (PerfeCTa™ SYBR
R Green FastMix™
for iQ™, Quanta Biosciences, Inc.) and loaded onto the
Lonza Mouse Stress Response 96 StellARray™ on a
BioRad iCycler. Data were analyzed using the Global
Pattern Recognition Analysis Tool version 2.0 http://
array.lonza.com/apps/gpr/.
Statistics
Comparisons between WT and KO mice were made
using ANOVA followed by Tukey’s post-hoc test for
incidences of pathologies including tumors, GST activ-
ities, tumor weights, and western blots. The Mann-
Whitney U-test (non-parametric) was used for tumor
multiplicities. Kaplan-Meier survival statistics were
employed. Additional tests are described in the figure
legends. For body weight data in the tumor study, Area
under the curve (AUC) was calculated for each animal
by the trapezoid method. Analysis of variance was used
to test for differences in AUC between groups.
Results
Premalignant Study
We first conducted a premalignant study, using the pro-
tocol described by Aldaz [12]. The duration of the pre-
malignant study was actually determined by the tumor
study. In this regard, the tumor study began 3 weeks
earlier than the premalignant study. As soon as palpable
mammary tumors were observed in the tumor study,
the premalignant study was terminated (10 weeks after
carcinogen). The results are shown in Figures 1, 2. Ana-
lyses of the whole mounts, H&E’s, and BrdU incorpora-
tion all pointed to the same conclusion. All mice treated
with DMBA exhibited a similar degree of premalignant
lesions, as characterized by atypical ductal hyperplasia
(ADH), and ductal carcinoma in situ (DCIS) (also
called early carcinoma) (Figure 2). None of the mice
treated with vehicle only developed any of these lesions
(Figure 1).
To verify that AUR was inducing GST in WT but not
in KO mice as previously observed [5], hepatic GST
activities were analyzed. The results are shown in Addi-
tional File 1: Figure S2. GST activities using both CDNB
and DCNB as substrates were significantly increased in
control WT mice fed the AUR diet, but not in control
KO mice fed AUR, as expected. In mice treated with
DMBA, GST activities were significantly increased in
WT mice fed both control and AUR diets using CDNB
as a substrate. Thus, it appeared that the DMBA treat-
ment was masking the effect of AUR in the WT mice.
In KO mice fed either control or AUR diets, GST activ-
ities using DCNB as a substrate were significantly lower
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mice overall had reduced GST activities compared to
WT, regardless of carcinogen treatment or diet. Thus
we concluded that the effects of AUR in WT vs. KO
mice was consistent with our previous report [5].
T h eb o d yw e i g h td a t af o rt h ep r e m a l i g n a n ts t u d yi s
shown in Additional File 1: Figure S3. At day 63 there
was no significant difference between the weights of the
five groups by ANOVA, p = 0.32. However, on day one
there are significant differences by ANOVA, p = 0.002.
Two ways of adjusting for this are ANCOVA using day
1 weights as a covariate. In this case the p value for
group differences is 0.24, still not significant. The other
method is to look at a time-group interaction with
Figure 1 Representative photomicrographs of the vehicle control groups from the premalignant study. From L-R: whole mounts (40×,
left panels), H&E’s (200×, middle panels) and BrdU staining (200×, right panel). Genotype, treatment, and diets are indicated at each row: [A] WT
control diet; [B] WT/AUR diet; [C] KO control diet; [D] KO/AUR diet. All photomicrographs were uniformly reduced in size to 70% of the original
picture in order to fit into the figure panels. Note, in the BrdU study, some background staining occurred, but this was also detected in the no
primary antibody control (data not shown). Nuclear staining of epithelial cells was not observed in the background control.
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groups (the small animals) are gaining faster than the
others. However, at day 63 the premalignant weights
were similar between groups, p = 0.32. Our overall con-
clusion is that it was unlikely that any differences in
body weight affected our experimental results. It also
shows that the AUR diet did not affect body weight, nor
did carcinogen exposure.
Tumor study
As mentioned above, the premalignant study began 3
weeks after the tumor study, and we terminated the
Figure 2 Representative photomicrographs of the carcinogen-treated groups from the premalignant study. From L-R: whole mounts
(40×, left panels), H&E’s (200×, middle panels) and BrdU staining (200×, right panel). Genotype, treatment, and diets are indicated at each row:
[A] WT/DMBA control diet; [B] WT/DMBA/AUR diet; [C] KO/DMBA control diet; [D] KO/DMBA/AUR diet. All photomicrographs were uniformly
reduced in size to 70% of the original picture in order to fit into the figure panels. Note, in the BrdU study, some background staining occurred,
but this was also detected in the no primary antibody control (data not shown). Nuclear staining of epithelial cells was not observed in the
background control.
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the tumor study. To our astonishment, there was a dra-
matic difference in the rate of growth and in the size of
the mammary carcinomas. However, there was no dif-
ference in mammary carcinoma latency (Table 1). As
shown in Figures 3, 4, Table 1, and Additional File 1:
Table S6, the Nrf2 KO mammary carcinomas grew at a
faster rate (Figure 3), had a significantly larger volume
(Figure 4A), and significantly greater tumor weight at
necropsy (Figure 4B). In the WT mice, the average rate
of mammary carcinoma growth was 28 mm
3/day (range
8-6 9m m
3/day), not including tumors ≤ 0.05 g (Figure
3A, Additional File 1: Table S6). A stable, immortalized
cell line has been isolated from WT 191 T1. In the KO
mice, the average rate of growth was 96 mm
3/day
(range 13 - 326 mm
3/day), not including tumors ≤ 0.05
g (Figure 3B and Additional File 1: Table S6). A stable,
immortalized cell line has been isolated from KO 151
T1. Tumors were measured by caliper and volume esti-
mated using the formula for a sphere. Only mammary
carcinomas as determined by both pathologists are
included in these charts. As shown in Figure 4A-B, the
caliper data was consistent with tumor weight at
necropsy. Aside from mammary carcinoma growth rate
and size, there were no other differences in mammary
carcinoma latency, incidence, or multiplicity. Photomi-
crographs of the mammary carcinomas are depicted in
Figure 5. In Figure 5B, a premalignant lesion is shown
surrounded by adipocytes. As shown in Figure 5C, some
of the mammary carcinomas invaded into muscle. How-
ever, it was not clear whether there were differences in
invasion between WT and KO mice. Thus the main
conclusion from the tumor study is that, despite no
apparent differences in between WT and KO mice in
the premalignant study, the KO mammary carcinomas
exhibited rapid, malignant progression.
Another major difference between the WT and KO
mice in the study was the incidence of high-grade lym-
phomas and cause of death. Although there was no sig-
nificant difference in the % of mice with any lymphoma,
there was a significantly higher incidence of high-grade
lymphoma (20% vs. 3% in WT vs. KO mice, respectively,
Table 2). When the any lymphoma data was stratified by
location, a significantly higher % incidence of spleen
with lymphoma involvement was observed (32% vs. 10%
in WT vs. KO, respectively). In fact, although there was
no difference in overall survival between WT and KO
mice (Figure 6A), many of the WT mice had to be
euthanized earlier on in the study due to illness caused
by lymphoma. However, the p-value for lymphoma-free
survival was not significant (p = 0.14). In contrast, more
of the KO mice had to be euthanized earlier on in the
study due to large palpable mammary tumor volume,
most of which were the mammary carcinomas. The
mammary tumor free survival was considerably different
between the groups (p = 0.001, Figure 6B). Taking into
consideration the most likely cause of death, there was a
two-fold greater percentage of KO mice that died/were
euthanized due to palpable tumor burden (60 ± 9% in
KO vs. 29 ± 8% in WT) (Additional File 1: Table S7).
We currently cannot explain the striking difference
between WT and KO mice in high-grade lymphoma
incidence and severity.
In addition to mammary carcinomas, many other
lesions were observed in the study (Table 2). However,
we included 10 age-matched control mice per genotype
(dosed with vehicle only), and euthanized 1 or 2 at a
time with each necropsy. There were no tumors or
other abnormalities in any of the control mice. In the
mammary region, by thorough evaluation of both whole
mounts and H&E’s, no difference in the % incidence of
hyperplasia or premalignant lesions (DCIS, early carci-
noma) was found. Other lesions typically observed in
DMBA-treated mice include adenoacanthomas, which
often have keratin pearls and other Squamous compo-
nents [12,18]. These tumors often grew very large as
well, and reached up to 20% incidence in the KO mice,
but only 6% incidence in the WT mice (p ≤ 0.1). Inter-
estingly, there appeared to be more skin lesions in the
WT mice, particularly early on in the study. These
included skin papillomas and/or Squamous cell carcino-
m a s .A l t h o u g ht h e%i n c i d e n c ew a s2 6 %i nt h eW T
mice and only 10% in the KO mice, these differences
were only marginally significant (p ≤ 0.1). Most of the
skin lesions occurred on areas of the body in which rub-
bing occurs, such as the chest, face, forepaws, or next to
the ear tag. Again the presence of these lesions was not
a surprise because it is known that oral administration
of DMBA leads to the formation of epidermal DMBA-
DNA adducts [19]. It is also known that wounding of
the skin also acts as a tumor promoter [20]. There was
a significantly higher incidence of hepatic steatosis in
the WT vs KO mice (24% vs 3%, respectively) and the
cause of this is unclear. Other lesions included ovarian
Table 1 Mammary carcinoma summary
Pathology analysis WT KO
No. of mice in study 34 30
No. of mice with MC 20 18
Tot. no. of MC’s3 3 2 9
Avg no. of MC’s/mouse 1.64 1.61
Cumulative total MC wt (g) 13.7 30.4
Average MC wt (g)/mouse 0.68 ± 0.15 1.69 ± 0.35**
MC latency 125 days 121 days
Summary of mammary carcinoma incidence, multiplicity, total cumulative
weight, latency, and average tumor weight per mouse. The weights of the
mammary carcinomas were significantly higher in KO than WT mice. MC,
mammary carcinoma. **p < 0.02.
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Page 7 of 17Figure 3 Mammary Carcinoma Results in Nrf2 WT vs. KO Mice. [A] Mammary carcinoma growth rate (y-axis denotes tumor volume, mm
3)i n
WT mice. [B] Mammary carcinoma growth rate (y-axis denotes tumor volume, mm
3) in KO mice.
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Page 8 of 17sex cord stromal tumors, but there was no difference in
incidence between WT and KO mice (12% vs. 7%,
respectively). Interestingly, the Nrf2 KO mice displayed
a significantly higher incidence of lung adenomas (46.7%
compared to 17.6%, p = 0.012).
Much of the molecular basis for the intriguing differ-
ence in WT vs. KO mice in mammary carcinoma pro-
gression remains to be determined. However, there was
no significant difference in protein carbonyls between
WT and KO mammary carcinomas (Figure 7A). Inter-
estingly, there was a ~2-fold increase in the expression
of the active form of NF-B( F i g u r e7 B )i nt h eK O
mammary carcinomas. However, a histopathological
analysis of the mammary carcinoma H&E’s revealed no
apparent difference in inflammatory components
between WT and KO. The active form of b-catenin was
also significantly increased by nearly 2-fold in the KO
mammary carcinomas (Figure 7C-D).
We hypothesized that there could be differences in the
stress pathway, so we conducted quantitative real-time
pcr on the mammary carcinomas (4 WT and 4 KO, Fig-
ure 8 and Table 3). Although there were no significant
p-values (likely due to the heterogeneity of these carci-
nomas), there were several “leads” that are listed in
Table 3. These include apparent decreases in caspase-3
and mmp-9, but increases in cadherin 1, thioredoxin
reductase 2, and glutathione peroxidase 3 in the KO
mammary carcinomas. Although we would expect to see
Figure 4 Mammary Carcinoma Results in Nrf2 WT vs. KO Mice. [A] Total cumulative volume of palpable mammary carcinomas as measured
by calipers (mm
3). [B] Total cumulative tumor weight of palpable mammary carcinomas as determined at necropsy (g).
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Page 9 of 17Figure 5 Histopathology results. [A] Representative H&E section of WT mammary carcinoma, as reviewed by pathologist. [B] Premalignant
lesion (DCIS) in a KO mouse. [C] Photomicrograph of H&E section of KO mammary carcinoma, as reviewed by pathologist. ** denotes invasion
into muscle. Magnification × 400.
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Page 10 of 17a decrease in caspase-3 (leading to reduced apoptosis in
the KO mammary carcinomas), we were surprised to
observe the apparent decrease in mmp-9, and higher
expressions of antioxidant genes. Without further analy-
sis, we can only speculate that these may be compensa-
tory responses to the tumor microenvironment.
The body weights of all mice in the tumor study,
including the vehicle control mice, are shown in Addi-
tional File 1: Figure S4. There was no overall statistical
difference between groups, p = 0.08. The Tukey HSD
post-hoc test was used to compare pairs of groups. No
significant differences were found, p-values ranged from
0.08 to 0.89 (box plot, Additional File 1: Figure S5).
These results suggest that body weight was not a factor
in the experimental results, and that carcinogen expo-
sure did not affect body weight. However, mice found to
be moribund were euthanized, so it is unlikely that
cachexia was involved in the study.
Discussion
The role of Nrf2 activation in the chemoprevention of
many types of cancer has been well-established [21].
However, little is known about the role of Nrf2 in the
prevention of mammary carcinogenesis. The current
study demonstrated that targeted deletion of Nrf2 in
mice treated with DMBA resulted in rapid, aggressive
mammary carcinoma growth rate, characterized by sig-
nificantly larger tumor volume and tumor weight. In
contrast, Nrf2 activation (through dietary exposure to
AUR) or deletion (KO mice) did not appear to affect the
formation of premalignant lesions. Induction of the so-
called “phase II detoxifying enzymes” would be expected
to block tumor initiation [22], so these results were sur-
Table 2 Incidence of lesions in Nrf2 mammary tumor
study
Lesion WT-% inc KO-% inc p-value
Mammary region
Hyperplasia 55.9 ± 0.5 46.7 ± 0.5
Pm (DCIS, early Ca) 67.6 ± 0.5 63.3 ± 0.5
Mam. carcinoma 58.8 ± 0.5 66.7 ± 0.5
Sebaceous 2.9 ± 0.2 3.3 ± 0.2
Adenoacanthoma 5.9 ± 0.2 20.0 ± 0.4 0.091
Lung mets (mc) 5.9 ± 0.2 6.7 ± 0.2
Sarcoma 8.8 ± 0.3 3.3 ± 0.2
Other (fibroadenoma, cyst) 8.8 ± 0.3 13.3 ± 0.3
Lymphomas (by location)
Lung 23.5 ± 0.4 16.7 ± 0.4
Spleen 32.4 ± 0.5** 10.0 ± 0.3 0.031
Liver 29.4 ± 0.5 16.7 ± 0.4
Mediastinal mass 35.3 ± 0.5 20.0 ± 0.4
Mammary gland 11.8 ± 0.3 6.7 ± 0.2
Lymph node 0 6.7 ± 0.2
Other (internal mass, bone) 0 10.0 ± 0.3
Mice with any lymphoma 47.1 ± 0.5 36.7 ± 0.5
Any high-grade lymphoma 20.6 ± 0.4** 3.3 ± 0.2 0.042
Other lesions
Lung adenomas 17.6 ± 0.4** 46.7 ± 0.5 0.012
Skin pap/carc 26.5 ± 0.5 10.0 ± 0.3 0.095
Liver steatosis 23.5 ± 0.4** 3.3 ± 0.2 0.020
Ovarian sex cord stromal 11.8 ± 0.3 6.7 ± 0.2
Values represent the mean incidence (% Inc.) of lesions ± SD (n = 34 WT, 30
KO). ** Significantly different from KO mice, p ≤ 0.05. Pm, premalignant
lesions, mc, mammary carcinoma. P-values are shown for differences that
were either significant (p ≤ 0.05) or marginally significant (p ≤ 0.1).
Figure 6 Kaplan-Meier Survival analysis of [A] overall survival,
[B] mammary tumor-free survival.
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Page 11 of 17prising. On the other hand, we have previously shown
that the linear furanocoumarins, such as imperatorin
and isopimpinellin, are more effective at suppressing
DMBA-DNA adduct formation compared to the simple
coumarins, limettin and coumarin [13]. Linear furano-
coumarins are much more potent inhibitors of the cyto-
chrome P4501 family of enzymes that bioactivate
DMBA [13]. In contrast, AUR and other simple coumar-
ins do not exhibit this effect. Thus, the apparent lack of
effect of AUR on premalignant lesions in the current
study should not be discouraging. We recently reported
that dietary administration of AUR delayed onset of N-
methylnitrosourea-induced mammary carcinomas in
rats, which corresponded to a decrease in cyclin D1 pro-
tein expression [23]. This suggests that AUR affects later
stages of mammary carcinogenesis, such as promotion
and/or progression.
Figure 7 Western blot analyses of mammary carcinomas. Panel A: Ratio of oxidized proteins: total protein in mammary carcinomas. Values
represent means ± SE (n = 7-8). No significant difference was observed between WT and KO. The oxyblot was repeated a second time with
additional samples (n = 9-12), and similar results were observed. Panel B: Ratio of phospho-p65-NF-B/total NF-B (normalized to total protein)
in mammary carcinomas. Values represent means ± SE (n = 5-6) of individual tumors. This ratio was significantly higher in the KO mammary
carcinomas. * Significant difference (ANOVA p < 0.05). Panel C: Representative western blot comparing WT and KO mammary carcinoma
expression of b-catenin. Top panel, active b-catenin, middle panel, total b-catenin, lower panel, b-actin (loading control). Tumor lysates from
individual mice were loaded on the gel as indicated at top of figure. Panel D: Summary of b-catenin results. Figures represent the ratio of
active/total b-catenin (means ± SE, n = 9-10). * Significant difference (ANOVA p < 0.05).
Figure 8 GPR results for q-rt-pcr Stress Response 96 well array.
KO mammary carcinomas are compared to WT as the control.
Figures represent fold-change.
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Page 12 of 17The model chosen for initiating carcinogenesis was
selected based on a report by Aldaz and colleagues that
pre-treatment with depot medroxyprogesterone acetate
increased DMBA-induced mammary tumor incidence,
and significantly shortened the latency [12]. Also there
were fewer non-mammary tumor related deaths (8%)
in their study compared to the DMBA only groups
(51%-81%). In our study, we observed a high level of
morbidity and mortality in the WT group (46% due to
lymphomas). However, the background strains of the
mice were different between our study and theirs (ICR
vs. CD2F1, respectively).
Understanding the molecular basis for the drastic differ-
ences between mammary carcinogenesis in WT vs. Nrf2
KO mice is critical. The 2-fold increase in NF-Ba c t i v a -
tion in Nrf2 KO mammary carcinomas was intruiguing
and suggests possible cross-talk between Nrf2 and NF-B.
This concept was explored recently by Tusi and colleagues
[24], who demonstrated that triazine derivatives, which
possess anti-cancer activities, inhibited the activation of
NF-Bb yH 2O2 in PC12 cells. The triazine derivatives
also induced HO-1, induced Nrf2 protein expression, and
increased GSH content. The conclusion was that the Nrf2
mediated neuroprotective effects of these triazine deriva-
tives may be due to suppression of NF-B. Thus, the exact
role of NF-B activation in mammary carcinogenesis in
the Nrf2 KO mice remains to be determined.
The increased expression of activated b-catenin in the
Nrf2 KO mammary carcinomas was also interesting. It
has been previously reported that the heterogeneity of
DMBA-induced mouse mammary carcinomas could be
due to changes in the Wnt pathway in mammary pro-
genitor cells [18]. Nucleoredoxin is a member of the
redox-catalyic family including thioredoxin, which is
regulated by Nrf2 activation [25]. Nucleoredoxin acts as
a redox-sensor that negatively regulates signaling of
Wnt/b-catenin by forming a complex with Dissheveled
(DVL) [26]. In the “on state”, Wnt binds to its receptor,
frizzled (FZD). DVL inhibits the b-catenin destruction
complex, thus b-catenin accumulates, translocates to the
nucleus, where it activates transcription factors for tar-
get genes [26]. Therefore, we hypothesized that the
active form of b-catenin would be elevated in the KO
mammary carcinomas, which was supported by our
data.
In regards to the quantitative real time pcr array, we
consider these results to be leads for future studies. We
will highlight a few of the top leads herein. The downre-
gulation of Casp3, a pro-apoptotic protein [27], in the
KO mammary carcinomas might suggest that the
tumors are more resistant to apoptosis, which could
explain why the rapid growth and size. However, upre-
gulation of Cdh1 and downregulation of Mmp9 are
counter-intuitive to the observed results. Cdh1 regulates
cellular adhesion, and loss of Cdh1 is associated with
invasion and metastasis [28]. Mmp9 is a gelatinase also
involved in tumor invasion [29]. Also, the striking
increase in thioredoxin reductase 2 (Txnrd2) and the
Table 3 Comparison of WT vs KO mice Quantitative real-time pcr array: mouse stress response pathway
Rank Well Gene Name Fold Change
1 A10 Casp3 caspase 3, apoptosis related cysteine protease -2.69
2 H02 Cdh1 cadherin 1 2.91
3 H12 Txnrd2 thioredoxin reductase 2, mitochondrial 3.53
4 A03 Mmp9 matrix metallopeptidase 9 -6.83
5 F03 Gpx3 glutathione peroxidase 3 13.2
6 C03 Hspb2 heat shock protein 2 1.66
7 G03 Gpx7 glutathione peroxidase 7 3.09
8 D06 Mmp2 matrix metallopeptidase 2 1.65
9 A12 Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5 -1.73
10 D05 Aprt adenine phosphoribosyl transferase -1.86
11 B06 Bcl2l1 BCL2-like 1 -1.59
12 F10 Myc myelocytomatosis oncogene -1.60
13 F06 Sod1 superoxide dismutase 1, soluble -1.74
14 E12 Rad9 RAD9 homolog (S. pombe) -1.86
15 C04 Trp53 transformation related protein 53 -1.82
16 H08 Xpa xeroderma pigmentosum, complementation grp A 1.49
17 F07 Aoc3 amine oxidase, copper containing 3 2.13
18 H10 Pklr pyruvate kinase liver and red blood cell 1.96
Global Pattern Recongition TM (GPR) Results for Mouse Stress Response 96 StellARray™. Four WT mammary carcinomas (125T3, 135T1, 191T3, and 139T6) were
compared to four KO mammary carcinomas (183T1, 165T1, 155T1, and 172T1). The selection of mammary carcinomas for the real-time pcr experiment was based
on the date of necropsy so that the mice would be fairly well age-matched. The average days on the study for the WT compared to Nrf2 KO mice were 166 vs.
170, respectively. Also, these tumors were strictly mammary adenocarcinomas, not mixed with lymphoma or adenoacanthoma. P-values ranged from 0.11 -0 . 2 4 ,
and so these results are considered “leads” not statistically significant.
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Page 13 of 17selenoproteins glutathione peroxidase 3 and 7 (Gpx3,
GPX7) may explain why there were no differences in oxi-
dized proteins in WT vs. KO mammary carcinomas. This
would then suggest that these genes are regulated by fac-
tors other than or in addition to Nrf2. Txnrd2 is a mito-
chondrial defense against oxidative stress [30]. Gpx3 is
expressed in plasma and normal kidney where it counter-
acts oxidative stress [31]. It can be increased at various
stages of cancer, but also possesses protective effects.
Gpx are regulated by Nrf2 and p63, which is a member
of the p53 family, but not p53 itself [31]. Overexpression
of Gpx inhibited p53-dependent H2O2 induced apoptosis
in human MCF-7 breast carcinoma cells. Gpx7 is
silenced in Barrett’s oesophagus and adenocarcinoma via
epigenetic mechanisms [32]. Again at this point we can
only speculate that these are compensatory mechanisms
as the KO carcinomas adapt to their environment.
In our study, the Nrf2 KO mice also displayed signifi-
cantly higher incidence of lung adenomas. It is clear
from the literature that under certain experimental con-
ditions, phytochemicals and other molecules that acti-
vate Nrf2 confer protection from the early stages of
carcinogenesis (reviewed in [4,33]). Enzymes that can
protect against oxidative stress and detoxify carcinogens
are induced, thus protecting the body from harmful che-
micals such aflatoxin B1 and benzo[a]pyrene. For exam-
ple, daily oral dosing of 125 mg oltipraz for a month in
humans increased the excretion of aflatoxin-mercapturic
acid [34]. In rodents treated with aflatoxin B1, dietary
exposure to oltipraz induced phase II carcinogen detoxi-
fying enzymes including GST, and conferred protection
against DNA adduct formation and tumorigenicity
[35,36]. In another example, dietary exposure to diben-
zoylmethane activated Nrf2/ARE and decreased the for-
mation of benzo[a]pyrene DNA adducts in A/J mouse
lungs [37]. With these and other examples in the litera-
ture, the chemopreventive agents were administered
prior to disease progression. Thus it may not be surpris-
ing that there were increased lung adenomas in the
Nrf2 KO mice treated with DMBA.
On the other hand, epidemiological evidence and
xenograft models with lung carcinoma cells have sug-
gested that Nrf2 is upregulated in cancer and that sup-
pression of Nrf2 may be a therapeutic target [38,39]. In
consideration of our findings with the published litera-
ture, the sequence of Nrf2 activation over time during
c a r c i n o g e n e s i sm a yb et h ek e yf a c t o ri nd e t e r m i n i n g
whether it is protective or stimulatory in cancer.
Whereas antioxidant enzymes may be preventive against
cancer development, in already transformed cells, these
enzymes may confer protective advantage of cancer cells
in the hostile tumor microenvironment [40,41]. In this
regard, Nrf2 upregulation of cellular antioxidant defense
may protect cancer cells from oxidative stress, and make
them more resistant to chemotherapy and radiation.
Furthermore, an N-terminal domain mutation of Keap-1
(C23Y) was identified in human breast cancer [42]. Nioi
and Nguyen demonstrated that this mutation impairs
the ability of Keap-1 to repress Nrf2 activity [43]. How-
e v e r ,w h a ti sn o tk n o w ni sw h e ni nt h ec a r c i n o g e n i c
process is Keap-1 is mutated. Carcinogenesis results in
compounding mutations, and by end-stage disease, cau-
sative factors can be difficult to discern. The potential
effects of chemopreventive phytochemicals in cancer
patients may not be clear. Recently, a comparison of
genetic vs. pharmacologic activation of Nrf2 using
Keap-1 knockout mice and a synthetic oleanane triterpe-
noid, respectively [44]. Distinct but overlapping genetic
changes exist, suggests that dietary intervention with
phytochemicals may not have the same effect as genetic
manipulation. Up to now, most of the Nrf2 manipula-
tions in cancer cells have been done using sh-RNA
against already transformed cancer cells. We hope that
our future characterization of the stable, immortalized
WT and Nrf2 KO mammary carcinoma cell lines we
developed will help address the conflicting role of Nrf2,
because Nrf2 was either present or knocked-out com-
pletely prior to cancer development.
In a broader sense, the current results may offer clues
into factors that drive rapid malignant progression.
These results are consistent with the idea that ROS can
act as signaling molecules to redox sensitive pathways
[25]. However, more studies will be necessary to identify
whether this phenomenon drives breast cancer progres-
sion in humans. If this is found to be the case, then
these pathways could be considered for therapeutic
intervention.
Conclusion
In conclusion, we have developed a mammary carcino-
genesis model in Nrf2 KO mice. Treatment with the
carcinogen, DMBA, resulted in the formation of prema-
lignant lesions in mouse mammary glands, but no differ-
ences in these premalignant lesions were observed
between WT and Nrf2 KO mice. Instead, Nrf2 KO mice
developed rapidly growing, aggressive mammary carci-
nomas that were larger than the WT mammary carcino-
mas. Although there was no difference in overall
survival between WT and KO mice, there was a signifi-
cant decline in mammary tumor-free survival in the KO
mice. The active forms of NF-Ba n db-catenin were
significantly elevated ~2-fold in the KO mammary carci-
nomas. Real-time quantitative pcr analysis suggested
that Casp3 was downregulated in the KO mammary car-
cinomas. Many other lesions were observed in the
tumor study, particularly lung adenomas, which were
more predominant in the Nrf2 KO mice. We conclude
that Nrf2 KO mice were more susceptible to DMBA-
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Page 14 of 17induced mammary carcinogenesis, particularly in terms
of tumor size, rate of growth, and mammary tumor-free
survival. Key factors involved in the rapid growth of
these carcinomas remain to be determined. Identifica-
tion of factors responsible for the rapid tumor growth
rate may provide insight into human breast cancer.
Additional material
Additional file 1: Additional Figures and Tables. Figure S1: Liver
cytosolic GST activity in the comparison study using CDNB and DCNB as
substrates. Female Nrf2 wild-type or knockout mice (age 6-8 weeks old)
were administered vehicle (corn oil, 0.1 ml per 25 g bw) or auraptene
(150 mg/kg bw) once a day for 3 consecutive days. At 24 h after the
final dose, mice were sacrificed and livers removed. Liver cytosolic
fractions were obtained by differential centrifugation. Glutathione S-
transferase activity (using either CDNB or DCNB as substrates) was
analyzed by the method of Habig. Figure S2. Liver cytosolic GST activity
in the premalignant study using CDNB and DCNB as substrates. Cont.,
control diet, AUR, auraptene diet *Significantly different from vehicle
control group with control (AIN76A) diet at p < 0.05 (ANOVA, Fischer’s
PLSD test), but not in the KO mice. DMBA groups, WT mice increased in
GST activities fed either auraptene or control diet vs. KO mice. Figure S3.
Body weight chart from premalignant study. The group of KO mice
dosed with carcinogen had a lower bw at the beginning of the study,
but they caught up by the end, where there was no significant
difference. Figure S4. Body weight chart for the tumor study. No major
changes in body weights were observed amongst the groups in the
tumor study. Body weights (mean ± SD) are plotted as a function of
days on the study. Figure S5. Box plot showing no major changes in
body weights were observed amongst the groups in the tumor study.
Figures represent area under the curve. Table S6. Rate of growth of
mammary carcinomas (linear phase) mm
3/day. *Rate of growth was
estimated by taking the difference in tumor volume from two dates (or
four dates for biphasic curves) in the linear phase of growth. Some
curves were wavy, so a best-fit line was drawn to estimate tumor
growth. WT mice: Many tumor remained dormant for a long time or
throughout the study–tumors that grew very slowly, never got big, or
were only found at necropsy, 117 T3, 176 T1, 181 T1, 146 T1, 125 T3, 127
T1, etc. Average (not including slow-growing tumors) = 28 mm
3/day.
KO mice: tumors that grew slowly, were small, or only found at necropsy:
164 T2, 184 T3, 154 T1-3, 117 T3, 176 T1, 181 T1. Average (not including
slow-growing tumors) = 96 mm
3/day. Table S7. Necropsy data for Nrf2
mammary carcinogenesis study. “Cause of death” defined as the most
likely cause of death. This includes the following: lymphomas causing
illness such as breathing difficulties, internal bleeding; Tumor burden,
mainly palpable tumors (mammary carcinomas, with a few
adenoacanthomas, and a rare occurrence of sebaceous gland tumors,
and hemangiomas); Other–either large skin papillomas, ill due to
unknown origin (thin), steatosis. Values represent the percentage of mice
per category means ± SE (n = 34 WT; 30, KO). **Significantly different
from WT mice p ≤ 0.02.
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